UPSIDA, JNPA Sign Pact to Position Lalitpur Pharma Park as Global Export Hub
In a significant move to enhance India’s pharmaceutical export infrastructure, the Uttar Pradesh State Industrial Development Authority and the Jawaharlal Nehru Port Authority have signed a strategic agreement to develop the Lalitpur Pharma Park into a global export hub .
The memorandum of understanding aims to provide seamless connectivity between northern India’s industrial clusters and international markets through world-class logistics and port integration. Under the pact, pharmaceutical products manufactured in Lalitpur will be transported via an advanced multi-modal transport system to JNPA, India’s largest container port, ensuring faster and more efficient exports.
A key feature of the agreement is the integration of the Dadri–Khurja rail link with the Western Dedicated Freight Corridor and Eastern Dedicated Freight Corridor , enabling cost-effective transportation and improved supply chain efficiency. This connectivity is expected to significantly boost export-import trade by facilitating smooth movement of both raw materials and finished pharmaceutical products.
The Lalitpur Pharma Park, spread across about 1,470 acres, is one of the largest upcoming pharmaceutical manufacturing clusters in North India. The project is expected to attract investments of over ₹12,000 crore and generate thousands of jobs, while promoting production of bulk drugs, APIs, and formulations.
The initiative aligns with the vision of Chief Minister Yogi Adityanath to position Uttar Pradesh as a major centre for pharmaceutical manufacturing and healthcare industries. The park is also designed to reduce India’s dependence on imports by strengthening domestic production of key pharmaceutical ingredients.
India remains one of the world’s leading pharmaceutical exporters, often referred to as the “pharmacy of the world.” The country exported pharmaceutical products worth around $25 billion in FY 2022–23 and supplies medicines to over 200 countries, with a strong presence in regulated markets such as the US and Europe.
The Indian pharmaceutical industry is valued at about $50 billion and is projected to grow rapidly in the coming years, driven by increasing global demand for generic medicines and vaccines.
Uttar Pradesh, while still emerging in the pharma export space compared to states like Gujarat, is expanding rapidly. The state recorded overall exports of about $19 billion in FY 2024–25, with pharmaceuticals identified as a key focus sector for future growth.
Recent policy initiatives, infrastructure projects, and investment outreach programmes have further strengthened the state’s pharmaceutical ecosystem, with the Lalitpur Pharma Park expected to play a crucial role in boosting exports from the region.
The UPSIDA–JNPA partnership marks a major step towards integrating Uttar Pradesh’s industrial growth with national logistics infrastructure. By improving connectivity, reducing logistics costs, and enhancing efficiency, the project is expected to significantly increase India’s competitiveness in global pharmaceutical markets while positioning Lalitpur as a key export hub.